Procter & Gamble Hygiene and Health Care Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹992Cr
- −1% YoY
- −20.5% QoQ
- Net profit
- ₹156Cr
- +1.3% YoY
- −42% QoQ
- Margin
- 21%
- −5 pp YoY
- −9 pp QoQ
Top 7 Personal Products companies on management guidance
See the sector's top 10 — free with your mobile number.
The short version
The company aims to grow ahead of the industry average, focusing on consistent and sustained growth rooted in a deep understanding of evolving consumer needs. The company aims to grow at a rate ahead of the industry average with consistent, sustained growth rooted in a deep understanding of evolving consumer needs and superior propositions.
From Procter & Gamble Hygiene and Health Care Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company aims to grow ahead of the industry average, focusing on consistent and sustained growth rooted in a deep understanding of evolving consumer needs.
- Growth strategy centers on driving category expansion by uncovering and serving new "jobs to be done" for consumers.
- Significant opportunity exists to grow consumption and innovation within existing categories, particularly by increasing household penetration among unserved and underserved consumers.
- Innovation pipeline is robust, with recent quarters showing strong new product introductions designed to attract new users and address new consumer needs.
- Feminine care category has substantial runway as penetration is under 50%, with market leadership maintained and growth driven by product upgrades and education.
- Healthcare category innovations such as Vicks Steam Pods and Zzzquil are seeing positive market response, supporting growth.
2 more points from Procter & Gamble Hygiene and Health Care Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Procter & Gamble Hygiene and Health Care Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
2 more points from Procter & Gamble Hygiene and Health Care Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Personal Products
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Procter & Gamble Hygiene and Health Care Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Procter & Gamble Hygiene and Health Care Ltd said on order book & pipeline — free account, 30 seconds.
Procter & Gamble Hygiene and Health Care Ltd — Quarterly revenue & net profit
Procter & Gamble Hygiene and Health Care Ltd Q4 FY25 results — key figures
| ₹ Cr | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 992 | 1,002 | -1% | 1,248 | -20.5% |
| Operating profit (EBITDA) | 210 | 257 | -18.3% | 371 | -43.4% |
| Operating margin | 21% | 26% | -5 pp | 30% | -9 pp |
| Profit before tax | 213 | 234 | -9% | 364 | -41.5% |
| Net profit (PAT) | 156 | 154 | +1.3% | 269 | -42% |
| EPS (₹) | 48.09 | 47.56 | +1.1% | 82.74 | -41.9% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹1.1K Cr, net profit ₹196 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What P & G Hygiene's management said in earlier quarters
Others in Personal Products this season
- Cupid (Q4 FY25)
125 crores by FY26, indicating +150% growth (Page 29, 18). Key concall takeaways from Cupid Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Gillette India (Q4 FY25)
Gillette India delivered a 12% sales growth and 40% profit growth in the past year, reflecting strong execution of their Integrated Growth Strategy. Key…
- Emami (Q4 FY25)
Dividend payouts were highlighted, with a total dividend of 1000% or Rs. Key concall takeaways from Emami Ltd's Q4 FY25 earnings call — and how it ranks…
- Colgate-Palmoliv (Q4 FY25)
The premium 30% urban segment remains resilient and continues to drive growth. Key concall takeaways from Colgate-Palmolive (India) Ltd's Q4 FY25 earnings call…
Potential multibaggers · Q2 FY27
Potential multibaggers in Personal Products
on management's own guidance
- Strong growth2
- Strong growth1
- EmamiGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Procter & Gamble Hygiene and Health Care Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Procter & Gamble Hygiene and Health Care Ltd Q4 FY25 results?
The company aims to grow ahead of the industry average, focusing on consistent and sustained growth rooted in a deep understanding of evolving consumer needs. The company aims to grow at a rate ahead of the industry average with consistent, sustained growth rooted in a deep understanding of evolving consumer needs and superior propositions.
What is Procter & Gamble Hygiene and Health Care Ltd share price analysis?
Procter & Gamble Hygiene and Health Care Ltd currently shows a neutral. The stock trades at a P/E of 34.8 with a market cap of ₹27,541 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Procter & Gamble Hygiene and Health Care Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
